SNTI

Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Wall Street analysts forecast SNTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNTI is 10.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Senti Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Senti Biosciences Inc. EPS for the last quarter amounts to -0.69 USD, decreased -89.06 % YoY.

Senti Biosciences Inc (SNTI) has 34 emplpoyees as of December 15 2025.

Today SNTI has the market capitalization of 34.44M USD.